| The heme oxygenase system: its role in liver inflammation. | |
| | |
MedLine Citation:
|
PMID: 12871038 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Heme Oxygenase is the rate-limiting enzyme in the degradation of heme into carbon monoxide (CO), iron and bilirubin. To date, three heme oxygenase isozymes have been identified: HO-1, HO-2 and HO-3. While HO-1 is structurally different from its counterparts, HO-2 and HO-3 are very similar (90% homology), with HO-3 being a poor heme catalyst. Of the three isozymes, HO-1 is believed to be the only inducible form. Constitutively expressed HO-2 has been identified in several organs including kidney and vascular smooth muscle, with the most abundant sources (and activity) being in the liver, brain, spleen and testes. Within the normal liver, HO-2 is constitutively expressed within hepatocytes, Kupffer cells, endothelial cells and Ito cells. Until recently, products of the HO reaction were regarded as potentially toxic waste destined only for excretion. However, this view is changing as evidence suggests that HO activity plays an important protective role against cellular stress during inflammatory diseases. Biliverdin is reduced to bilirubin, which has been shown to possess potent antioxidative properties. CO, which is produced in equimolar concentrations to biliverdin and ferrous iron during heme oxidation by HO, may function as a second messenger stimulating soluble guanylate cyclase (sGC) and regulating vascular tone in combination with the free radical gas NO. CO may also possess anti-inflammatory properties such as the capacity to inhibit platelet aggregation, or the expression of pro-inflammatory cytokines. Recently, it has been shown that CO regulates bile formation and bile flow. We review the functional role of HO in liver and the potential application of HO-1 in therapeutic approaches to the treatment of inflammation. |
| | |
Authors:
|
Christian Wunder; Richard F Potter |
Related Documents
:
|
10900228 - Hepatic and central nervous system cytochrome p450 are down-regulated during lipopolysa... 22510408 - Ribosomal protein s3 interacts with tradd to induce apoptosis through caspase dependent... 19385008 - Accelerative effect of leflunomide on recovery from hepatic fibrosis involves trail-med... 14689698 - Pathogenesis and pathophysiology of yellow fever. 10556858 - In vitro and in vivo activation of polymorphonuclear leukocytes in response to particul... 17848168 - The mcf1 toxin induces apoptosis via the mitochondrial pathway and apoptosis is attenua... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current drug targets. Cardiovascular & haematological disorders Volume: 3 ISSN: 1568-0061 ISO Abbreviation: Curr Drug Targets Cardiovasc Haematol Disord Publication Date: 2003 Sep |
Date Detail:
|
Created Date: 2003-07-21 Completed Date: 2004-05-05 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101123341 Medline TA: Curr Drug Targets Cardiovasc Haematol Disord Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 199-208 Citation Subset: IM |
Affiliation:
|
Klinik für Anaesthesilogie, Julius-Maximilians-Universität Würzburg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Bilirubin / metabolism Biliverdine / metabolism Carbon Monoxide / metabolism Ferritins / metabolism Gene Therapy Heme Oxygenase (Decyclizing) / biosynthesis, genetics, metabolism* Heme Oxygenase-1 Hepatitis / enzymology, metabolism*, therapy Humans Isoenzymes / metabolism Liver / enzymology, pathology Membrane Proteins Up-Regulation |
| Chemical | |
Reg. No./Substance:
|
0/Isoenzymes; 0/Membrane Proteins; 114-25-0/Biliverdine; 630-08-0/Carbon Monoxide; 635-65-4/Bilirubin; 9007-73-2/Ferritins; EC 1.14.99.3/HMOX1 protein, human; EC 1.14.99.3/Heme Oxygenase (Decyclizing); EC 1.14.99.3/Heme Oxygenase-1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: GABA transporters and GABA-transaminase as drug targets.
Next Document: Novel immunotherapeutic strategies for invasive fungal disease.